{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:22:24Z","timestamp":1791397344487,"version":"4.3.3"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>The association between tumour necrosis factor inhibitors [TNFi] and malignancy in patients with inflammatory bowel disease [IBD] is not well understood. Our aim was to systematically evaluate the impact of TNFi use on risk of malignancy in IBD patients in daily clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched Pubmed, Embase and Scopus until March 1, 2020 for observational cohort studies on adult IBD patients reporting malignancy occurrence and TNFi use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-eight studies [20 retrospective and eight prospective] were included, involving 298 717 IBD patients. Mean age at inclusion ranged from 28 to &amp;gt;65 years. Mean follow-up varied from 7 to 80 months. Infliximab was the most frequently used TNFi [13\/28 studies, 46.4%], followed by adalimumab [3\/28, 10.7%], while both infliximab and adalimumab were evaluated in five studies [17.8%]. In total, 692 malignancies were diagnosed in IBD patients treated with TNFi, accounting for an overall occurrence of 1.0%. The most frequent malignancies were non-melanoma skin cancers [123\/692, 17.8%], digestive malignancies [120\/692, 17.3%] and haematological malignancies [106\/692, 15.3%]. The association between TNFi and malignancy was evaluated in 11 studies [39.3%]: no significant association was found in ten studies, while an increased risk of lymphoma in patients exposed to TNFi was reported in one study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>TNFi treatment is not associated with an increased risk of malignancy in IBD patients in real-life settings. Further large studies are needed to assess the prognosis of patients exposed to TNFi and risk of recurrence or new cancers in subjects with personal malignancy history.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaa186","type":"journal-article","created":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T19:14:57Z","timestamp":1599506097000},"page":"840-859","source":"Crossref","is-referenced-by-count":62,"title":["TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6412-932X","authenticated-orcid":false,"given":"Marie","family":"Muller","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Nancy University Hospital, University of Lorraine, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nancy University Hospital, University of Lorraine, Nancy, France"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6102-6579","authenticated-orcid":false,"given":"Stefanos","family":"Bonovas","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy"},{"name":"IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center\u2013IRCCS, Rozzano Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy"},{"name":"IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center\u2013IRCCS, Rozzano Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nancy University Hospital, University of Lorraine, Nancy, France"},{"name":"Inserm U1256 \u2018Nutrition\u2014Genetics and exposure to environmental risks\u2013NGERE\u2019, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"key":"2021050415271004000_CIT0001","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.crohns.2013.09.009","article-title":"A tale of two diseases: the history of inflammatory bowel disease","volume":"8","author":"Mulder","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2021050415271004000_CIT0002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn\u2019s disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2021050415271004000_CIT0003","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2021050415271004000_CIT0004","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2012.01.010","article-title":"Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies","volume":"10","author":"Jess","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021050415271004000_CIT0005","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/2050640620919254","article-title":"Genomic and molecular alterations in human inflammatory bowel disease-associated colorectal cancer","volume":"8","author":"Muller","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"2021050415271004000_CIT0006","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/ibd\/izx100","article-title":"Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part I","volume":"24","author":"Knowles","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2021050415271004000_CIT0007","doi-asserted-by":"crossref","first-page":"704","DOI":"10.7326\/M13-2403","article-title":"Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis","volume":"160","author":"Danese","year":"2014","journal-title":"Ann Intern Med"},{"key":"2021050415271004000_CIT0008","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.gastro.2014.10.011","article-title":"Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn\u2019s disease: a network meta-analysis","volume":"148","author":"Hazlewood","year":"2015","journal-title":"Gastroenterology"},{"key":"2021050415271004000_CIT0009","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrgastro.2015.135","article-title":"Biologic agents for IBD: practical insights","volume":"12","author":"Danese","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2021050415271004000_CIT0010","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2021050415271004000_CIT0011","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/ibd.20211","article-title":"Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?","volume":"13","author":"Jones","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"2021050415271004000_CIT0012","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/ajg.2011.283","article-title":"Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease","volume":"106","author":"Herrinton","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2021050415271004000_CIT0013","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Andersen","year":"2014","journal-title":"JAMA"},{"key":"2021050415271004000_CIT0014","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"2021050415271004000_CIT0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/apt.12624","article-title":"Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-\u03b1 therapy in inflammatory bowel disease","volume":"39","author":"Williams","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2021050415271004000_CIT0016","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021050415271004000_CIT0017","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions.","author":"Higgins","year":"2020"},{"key":"2021050415271004000_CIT0018","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2021050415271004000_CIT0019","author":"Ottawa Hospital Research Institute."},{"key":"2021050415271004000_CIT0020","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/gut.2003.018515","article-title":"Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County","volume":"53","author":"Ljung","year":"2004","journal-title":"Gut"},{"key":"2021050415271004000_CIT0021","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.3748\/wjg.v13.i39.5238","article-title":"Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up","volume":"13","author":"Caviglia","year":"2007","journal-title":"World J Gastroenterol"},{"key":"2021050415271004000_CIT0022","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/0002018-200831120-00009","article-title":"Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands","volume":"31","author":"de Vries","year":"2008","journal-title":"Drug Saf"},{"key":"2021050415271004000_CIT0023","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gut.2008.163642","article-title":"Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study","volume":"58","author":"Fidder","year":"2009","journal-title":"Gut"},{"key":"2021050415271004000_CIT0024","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2036.2008.03919.x","article-title":"Efficacy and complications of adalimumab treatment for medically-refractory Crohn\u2019s disease: analysis of nationwide experience in Scotland (2004-2008)","volume":"29","author":"Ho","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2021050415271004000_CIT0025","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1365-2036.2008.03890.x","article-title":"Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England","volume":"29","author":"Russo","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2021050415271004000_CIT0026","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2036.2008.03882.x","article-title":"The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up","volume":"29","author":"Lees","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2021050415271004000_CIT0027","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn\u2019s disease","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"key":"2021050415271004000_CIT0028","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2036.2009.04206.x","article-title":"Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice","volume":"31","author":"Zabana","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"2021050415271004000_CIT0029","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/ibd.21290","article-title":"Safety of infliximab in Crohn\u2019s disease: a large single-center experience","volume":"16","author":"Hamzaoglu","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"2021050415271004000_CIT0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","article-title":"Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease","volume":"9","author":"Cottone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021050415271004000_CIT0031","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ibd.21416","article-title":"Cancer in Crohn\u2019s Disease patients treated with infliximab: a long-term multicenter matched pair study","volume":"17","author":"Biancone","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2021050415271004000_CIT0032","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/MEG.0b013e3283479125","article-title":"Safety of infliximab in 10 years of clinical practice","volume":"23","author":"O\u02bcDonnell","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2021050415271004000_CIT0033","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10620-012-2405-z","article-title":"Infliximab for Crohn\u2019s disease: the first 500 patients followed up through 2009","volume":"58","author":"Seminerio","year":"2013","journal-title":"Dig Dis Sci"},{"key":"2021050415271004000_CIT0034","first-page":"685","article-title":"Adenocarcinoma associated with perianal fistulas in Crohn\u2019s disease","volume":"33","author":"Ogawa","year":"2013","journal-title":"Anticancer Res"},{"key":"2021050415271004000_CIT0035","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/pds.3621","article-title":"Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies: malignancy risk in IBD treatment","volume":"23","author":"Beigel","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021050415271004000_CIT0036","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/ecco-jcc\/jjv032","article-title":"Incidence, management, and course of cancer in patients with inflammatory bowel disease","volume":"9","author":"Algaba","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2021050415271004000_CIT0037","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/MIB.0000000000000457","article-title":"Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a quebec claims database study","volume":"21","author":"Kopylov","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2021050415271004000_CIT0038","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.3748\/wjg.v21.i11.3282","article-title":"Real-life outcome of anti-tumor necrosis factor \u03b1 in the ambulatory treatment of ulcerative colitis","volume":"21","author":"Baki","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2021050415271004000_CIT0039","article-title":"Five-year safety data from ENCORE, a European observational safety registry for adults with Crohn\u2019s disease treated with infliximab [Remicade \u00ae] or conventional therapy","volume":"11","author":"D\u2019Haens","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2021050415271004000_CIT0040","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cgh.2015.07.037","article-title":"Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents","volume":"14","author":"Axelrad","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021050415271004000_CIT0041","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"2021050415271004000_CIT0042","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41395-018-0360-9","article-title":"Malignancies in inflammatory bowel disease: frequency, incidence and risk factors-results from the Swiss IBD cohort study","volume":"114","author":"Scharl","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2021050415271004000_CIT0043","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/ibd\/izx072","article-title":"Infliximab for Crohn\u2019s disease: more than 13 years of real-world experience","volume":"24","author":"Lichtenstein","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2021050415271004000_CIT0044","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s41395-018-0098-4","article-title":"Open: lymphoma risk and overall safety profile of adalimumab in patients with Crohn\u02bcs disease with up to 6 years of follow-up in the PYRAMID registry","volume":"113","author":"D\u02bcHaens","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2021050415271004000_CIT0045","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cgh.2019.05.027","article-title":"Efficacy and safety of tumor necrosis factor antagonists in treatment of internal fistulizing Crohn\u2019s disease","volume":"18","author":"Bouguen","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021050415271004000_CIT0046","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/ecco-jcc\/jjz048","article-title":"Five-year safety data from OPUS, a european observational safety registry for adults with ulcerative colitis treated with originator infliximab [Remicade\u00ae] or conventional therapy","volume":"13","author":"Pan\u00e9s","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2021050415271004000_CIT0047","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"2021050415271004000_CIT0048","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"2021050415271004000_CIT0049","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S2468-1253(19)30362-0","article-title":"Anti-tumour necrosis factor-\u03b1 therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study","volume":"5","author":"Waljee","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaa186\/33996104\/jjaa186.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/15\/5\/840\/37790185\/jjaa186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/15\/5\/840\/37790185\/jjaa186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T15:29:21Z","timestamp":1620142161000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/15\/5\/840\/5904280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,9,11]]},"published-print":{"date-parts":[[2021,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa186","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,4]]},"published":{"date-parts":[[2020,9,11]]}}}